Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CYBN SEC filings page on Stock Titan aggregates Cybin Inc.’s regulatory disclosures as a foreign issuer, giving investors structured access to the company’s official documents. Cybin files with the U.S. Securities and Exchange Commission primarily on Form 40-F and Form 6-K, and also uses Form 25 for listing changes. These filings are central to understanding the company’s clinical-stage neuropsychiatry business, its capital structure, and its transition between stock exchanges.
Form 6-K submissions for Cybin typically include interim consolidated financial statements, management’s discussion and analysis, certifications of interim filings, and news releases. Many 6-Ks also incorporate material change reports, equity distribution agreements, and prospectus-related documents by reference into Cybin’s registration statements on Form F-10. For a company developing drug candidates such as CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, these filings provide context on how clinical programs are funded and governed.
The filings page also features Cybin’s Form 25, which notifies the SEC of the voluntary removal of its common shares from listing and registration on the NYSE American. This document confirms that the company has complied with the exchange’s rules and the requirements for voluntary withdrawal, and it aligns with Cybin’s news release describing its plan to transfer its U.S. listing to the Nasdaq Global Market and to change its trading symbol from CYBN to HELP.
On Stock Titan, each new Cybin filing from EDGAR is captured and presented with AI-powered summaries that explain the purpose and key points of documents such as 6-Ks, F-10 registration statements, and the Form 25 delisting notice. This helps readers quickly understand how Cybin reports its financial results, documents material changes, and manages its listing status, while still allowing direct access to the underlying SEC filings for detailed review.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 2,397,721 Common Shares (4.8%) of Cybin Inc.
The filing states these reporting persons acquired beneficial ownership in excess of 5% on 03/19/2026 but ceased to be beneficial owners of more than 5% by the date of this Schedule 13G filing. The submission includes a Joint Filing Agreement dated 03/25/2026.
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K highlighting the appointment of Jill Conwell as Chief People Officer, effective immediately. She brings more than two decades of life sciences leadership across organizational strategy, talent development, communications, and investor relations.
Helus Pharma is a clinical stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions. Its lead program HLP003 is in Phase 3 for adjunctive treatment of major depressive disorder with FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 for generalized anxiety disorder.
Cybin Inc., operating as Helus Pharma, reported positive topline Phase 2 results for HLP004 in generalized anxiety disorder (GAD). In adults with moderate-to-severe GAD who remained symptomatic on standard antidepressant therapy, adjunctive 20 mg HLP004 achieved a mean 10.4-point reduction in Hamilton Anxiety Rating Scale scores at six weeks (p<0.0001), on top of standard of care.
Across the pooled study population, 67% were responders and 39% were in remission at six months. Treatment was generally well-tolerated with no drug-related serious adverse events or suicidality-related safety signals, and the acute drug effects lasted about 90 minutes with most Phase 1 participants ready for discharge within roughly three hours.
Cybin Inc. filed a Form 6-K to correct how certain previously filed documents are linked to its Canadian shelf registration in the United States. The company is now incorporating Exhibits 99.1-99.4 by reference into its Form F-10 registration statement with file number 333-292294.
These exhibits include interim consolidated financial statements and related management discussion and analysis for the three and nine months ended December 31, 2025, along with news releases dated February 10 and February 13, 2026. The filing replaces an earlier, inadvertent cross-reference to a different Form F-10 registration statement (file number 333-289139).
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K that incorporates a news release into its Canadian F-10 shelf. The release announces that former Pfizer Executive Vice President and Chief Medical Officer Dr. Freda Lewis-Hall has joined Helus Pharma’s Board of Directors and will chair its Scientific Advisory Committee.
The company highlights her four decades of experience in psychiatry, drug development, and global medical leadership, including roles at major biopharmaceutical companies. The filing also reiterates Helus Pharma’s focus on novel serotonergic agonists, including HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder, both aimed at serious mental health conditions.
Cybin Inc., doing business as Helus Pharma, has appointed Michael Cola as Chief Executive Officer, effective February 10, 2026. The company highlights this leadership change as it advances a pipeline of next-generation mental health therapies toward key clinical and corporate milestones.
Cola brings more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and serving as President and CEO of Avalo Therapeutics. He has also held senior roles at Astra-Merck, AstraZeneca, and served on boards of Phathom Pharmaceuticals and Sage Therapeutics.
OrbiMed Advisors LLC and OrbiMed Capital LLC report significant ownership stakes in Cybin Inc.’s common stock. OrbiMed Advisors reports beneficial ownership of 1,417,900 shares, or 2.8% of the class, while OrbiMed Capital reports 2,422,600 shares, or 4.9% of the class.
Together, the reporting persons hold 7.7% of Cybin’s common shares in the aggregate on behalf of other persons entitled to dividends or sale proceeds. The positions are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Cybin.
Cybin Inc., operating commercially as Helus Pharma, reports that Nature Medicine has published results from a Phase 2a randomized, placebo-controlled trial of SPL026 in adults with moderate-to-severe major depressive disorder. The single 21.5 mg intravenous dose met the primary endpoint, delivering statistically and clinically meaningful reductions in Montgomery-Åsberg Depression Rating Scale scores at two weeks versus placebo (mean difference: -7.35). Antidepressant effects appeared within one week, were sustained to three months, and some participants improved for up to six months, with no treatment-related serious adverse events reported. Response rates at Week 2 were 35% for SPL026 versus 12% for placebo, and remission rates were 29% versus 12%. Although intravenous SPL026 is not being advanced, the data support Helus’s short-acting serotonergic agonist approach and inform its HLP004 program, with Phase 2 topline data in generalized anxiety disorder expected in Q1 2026.
Tang Capital Management and related entities have exited their stake in Cybin Inc. In Amendment No. 3 to a Schedule 13G, Tang Capital Management, Kevin Tang, and affiliated partnerships and corporations report beneficial ownership of 0 shares of Cybin common stock, or 0% of the class, as of December 31, 2025.
The filing confirms they no longer have sole or shared voting or dispositive power over any Cybin shares and state that the securities were not acquired or held to change or influence control of the company.
Deep Track Capital and affiliated entities report owning 2,391,505 Cybin Inc. common shares, representing 4.74% of the class as of December 31, 2025. The position includes 537,250 warrants exercisable into common stock, subject to a 9.99% maximum beneficial ownership limitation.
The ownership calculation uses 50,431,381 shares, based on 49,894,131 common shares outstanding as of December 19, 2025 plus the warrants counted up to the stated cap. The filers certify the holdings are not for the purpose of changing or influencing control of Cybin.